SCHEMBL2409299

SCHEMBL2409299

COc1cccc(CC(=O)c2c(O)c3cccnc3n(-c3ccccc3)c2=O)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TOP2A P11388 2/20 0.49
ALDH1A1 P00352 2/20 0.48
MAPT P10636 1/20 0.46
THRB P10828 1/20 0.46
GAA P10253 2/20 0.44
MEN1 O00255 1/20 0.44
PSMD14 O00487 1/20 0.44
KMT2A Q03164 1/20 0.44
LIPG Q9Y5X9 1/20 0.44
KAT2B Q92831 2/20 0.44
CASP3 P42574 1/20 0.44
CASP7 P55210 1/20 0.44
CNR2 P34972 1/20 0.44
PKM P14618 1/20 0.43
RECQL P46063 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
POLB P06746 1/20 0.43
PDE1A P54750 1/20 0.43
PDE1B Q01064 1/20 0.43
USP2 O75604 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2409859 0.92 FEN1 (0.42) TOP2AALDH1A1MAPTGAAMEN1
SCHEMBL2414794 0.89 PTGDR2 (0.46) ALDH1A1MAPTTHRBPKMSMN1; SMN2
SCHEMBL2409456 0.87 PDE1A (0.51) ALDH1A1MAPTCNR2RECQLPDE1A
SCHEMBL2409528 0.87 MEN1 (0.46) ALDH1A1MAPTGAAMEN1KMT2A
SCHEMBL2407463 0.85 LIPG (0.45) ALDH1A1MAPTGAAMEN1PSMD14
SCHEMBL2411153 0.85 MAPT (0.40) MAPTGAAMEN1PSMD14KMT2A
SCHEMBL2409401 0.84 PDE4A (0.49) TOP2AALDH1A1MAPTTHRBMEN1
SCHEMBL4185730 0.84 PDE4B (0.43) TOP2AALDH1A1
SCHEMBL4187682 0.83 PDE4B (0.43) TOP2AMAPTCNR2PDE1APDE1B
SCHEMBL4185752 0.83 TP53 (0.47) MAPTMEN1KMT2APOLBPDE1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1559716-B1 PYRAZOLONAPHTHYRIDINE DERIVATIVE ASKA PHARM CO LTD (JP) 2011-09-14 EP disclosed
US-20100093782-A1 Pyrazolonaphthyridine derivatives KANAZAWA HASHIME 2010-04-15 US disclosed
US-7608716-B2 Pyrazolonaphthyridine derivative ASKA PHARMACEUTICAL CO., LTD. (JP) 2009-10-27 US disclosed
US-20060040972-A1 Pyrazolonaphthyridine derivative ASKA PHARMACEUTICAL CO., LTD. (JP) 2006-02-23 US disclosed
EP-1559716-A1 PYRAZOLONAPHTHYRIDINE DERIVATIVE Grelan Pharmaceutical Co., Ltd. (JP) 2005-08-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060040972-A1 Pyrazolonaphthyridine derivative PDE3B, PDE3A, PDE4A TOP2A 2204/4885ALDH1A1 909/4885MAPT 4759/4885
US-20100093782-A1 Pyrazolonaphthyridine derivatives PDE3B, PDE3A, PDE4A TOP2A 2354/4885ALDH1A1 997/4885MAPT 4771/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.